Reevaluation of CBE value of BPA for hepatocytes
Reevaluation of CBE value of BPA for hepatocytes
复制标题
DOI：
10.1016/j.apradiso.2020.109159
复制
发表时间：
2020-07-01
影响因子：
1.6
通讯作者：
Suzuki, Minoru
中科院分区：
文献类型：
--
作者：
Ono, Koji;Tanaka, Hiroki;Suzuki, Minoru
为探讨硼中子俘获治疗（BNCT）肝肿瘤的方法，实验测定了硼苯丙氨酸（BPA）对肝细胞的复合生物学效应（CBE）。在这项研究中，对先前的值进行了严格的重新评估。在以往的实验研究中，剂量的β分量的贡献被忽略的X射线的响应曲线。通过将普通微核（MN）试验中获得的α/β值与MN阴性细胞分数（MN（-）F）-剂量曲线相结合，估计X射线剂量细胞存活曲线。该曲线与硼中子俘获反应（BNCR）剂量曲线进行了比较。结果，剂量接近0戈伊时CBE值为4，剂量接近4.5戈伊时降至约1.0。新值小于先前值4.2。这表明正常肝脏的生物等效剂量低于先前的预期。因此，可以对肿瘤给予更高的剂量。
The compound biological effectiveness (CBE) value of boronophenylalanine (BPA) for hepatocytes was experimentally determined for the purpose of boron neutron capture therapy (BNCT) for liver tumors. In this study, the critical reevaluation of previous value was performed. In previous experimental studies, the contribution of beta component of dose was ignored in the response curve to X-ray. X-ray dose cell survival curves were estimated by combining the alpha/beta values obtained in the ordinary micronucleus (MN) assay with the curve of MN-negative cell fraction (MN(-)F) to dose. This curve was compared to the boron neutron capture reaction (BNCR) dose curve. As a result, the CBE value was 4 at doses close to 0 Gy, decreasing to about 1.0 at doses close to 4.5 Gy. The new value is smaller than the previous value 4.2. This indicates that the bioequivalent dose to normal liver is lower than previously expected. Therefore, higher doses can be given to the tumor.